Bone turnover markers in children living with HIV remaining on ritonavir- boosted lopinavir or switching to efavirenz.
Background: We previously found lower bone mass but similar bone turnover in pre-pubertal children living with HIV (CLWH) on a ritonavir-boosted lopinavir (LPV/r)-based vs. efavirenz-based antiretroviral therapy regimen 2 years after switch. Here, we evaluate if bone turnover differed between the groups close to the time of switch.
Author List: Shiau S, Yin MT, Strehlau R, Shen J, Abrams EJ, Coovadia A, Kuhn L, Arpadi SM.
Journal Name: Bone. 2020 Sep;138:115500. doi: 10.1016/j.bone.2020.115500. Epub 2020 Jun 23. PMID: 32590137.